Biomarkers and Imaging Markers for ICH

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorSouthwest Hospital, China

About this trial

Intracerebral hemorrhage (ICH) is a subtype of stroke associated with high mortality and disability. Basic and clinical research has contributed to our understanding of the complex pathophysiology in ICH. However, questions regarding acute diagnosis, therapeutic decisions, and prognostication of ICH remain unanswered. Molecular biomarkers and imaging markers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction and magnetic resonance imaging (MRI) scan in ischemic stroke. Therefore, the investigators aim to discovery the potential biomarkers by screening samples of blood, cerebral spinal fluid, urine, saliva, and even tissues (if available) from ICH patients, and imaging markers via serial multimodality imaging scans such as computed tomography(CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), etc. These molecular and imaging markers would assist in contributing additional information to current tools for onset warning, diagnosis, therapy monitoring, risk stratification, intervention and prognosis for ICH patients.

Eligibility criteria

Qualifiers

Individuals aged 18-80 years

Hematoma size is more than 5 ml

Evidence of a spontaneous ICH on CT scan

Patient within 72 hours of ictus

Disqualifiers

Individuals with age < 18 years or > 80 years

Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases.

ICH secondary to tumor or trauma..

If the haematological effects of any previous anticoagulants are not completely reversed.

Trial design

Treatments tested in this trial

  • body sample collection and imaging scan

Treatment groups

200 Participants
are divided into 2 treatment groups

Sponsors and collaborators